X

Test-to-Treat* can help you get tested for COVID-19 and, if appropriate, receive treatment all in the same location.

*This link will take you to a website that is owned and operated by HHS. Pfizer is not responsible for the content or services of this site.

Find Locations1-800-232-0233 (TTY 888-720-7489)

Test-to-Treat* can help you get tested for COVID-19 and, if appropriate, receive treatment all in the same location.

*These links will take you to a website that is owned and operated by HHS. Pfizer is not responsible for the content or services of this site.

Find Locations1-800-232-0233 (TTY 888-720-7489)
FDA EUA LetterFact SheetsFACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERSHOJA INFORMATIVA PARA PACIENTES, PADRES Y CUIDADORES FICHE D’INFORMATION POUR LES PATIENTS,
LES PARENTS ET LES SOIGNANTS
FOLHETO INFORMATIVO PARA DOENTES,
PAIS E PRESTADORES DE CUIDADOS
صحيفة الحقائق للمرضى واآلباء ومقدمي الرعايةFACT SHEET FOR HEALTHCARE PROVIDERSHOJA INFORMATIVA PARA PROVEEDORES
DE ATENCIÓN MÉDICA
FICHE D’INFORMATION DESTINÉE AUX PROFESSIONNELS DE SANTÉ FICHA INFORMATIVA PARA PRESTADORES
DE CUIDADOS DE SAÚDE
صحيفة الحقائق الخاصة بمقدمي الرعاية الصحية
Healthcare Provider Website

Menu

HomeHow to TakePossible Side EffectsFrequently Asked QuestionsResources
Resources

PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Testing and Telehealth Resources


Notice: The below links are provided as a resource to our visitors, and do not imply an endorsement or recommendation of a particular test or telehealth provider by Pfizer, nor an endorsement of any Pfizer product by a company, provider, or platform. 

Test for COVID-19

Click on the links below to learn about in-office and at-home COVID-19 rapid-testing options.

This is not an exhaustive list of COVID-19 testing options. Please visit covidtests.gov, a resource provided and managed by the U.S. Department of Health and Human Services, to order free at-home COVID-19 tests and for other related information, including where you may find free testing sites near you. 

Pfizer does not own or operate any of the below websites, or the products that they furnish, and Pfizer accepts no responsibility or liability for them.

Abbott
Quidel
Schedule a Telehealth Visit

If you do not have a healthcare provider or your healthcare provider is not available, you may be able to connect with one through telehealth services. You can visit one of the following sites to connect with a healthcare provider by phone, chat, or video.

Pfizer does not own or operate any of these telehealth platforms, or the services they or their providers may furnish, and Pfizer accepts no responsibility or liability for them.

Amwell
Doctor On Demand 
Good Rx
eMed

Providers for these telehealth platforms were selected based on their ability to provide COVID-19–related services in a traditional healthcare, physician office, or clinic setting. Providers or telehealth companies do not pay a fee to Pfizer for inclusion on this website. 

If these telehealth platforms match users with providers, the selection of a particular provider is determined by the criteria set by the platform and/or provider, not Pfizer. All treatment decisions are at the sole discretion of the provider based on the patient’s individual needs and risk-benefit profile.

Downloads

FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS
 

Revised 8/5/22

Download

HOJA INFORMATIVA PARA PACIENTES, PADRES Y
CUIDADORES

Revisado 28 de junio de 2022

Download

FICHE D’INFORMATION POUR LES PATIENTS, LES PARENTS ET
LES SOIGNANTS

Révisé le 28 juin 2022

Download

FOLHETO INFORMATIVO PARA DOENTES, PAIS E PRESTADORES
DE CUIDADOS

Revisto 28 de junho de 2022

Download

صحيفة الحقائق للمرضى واآلباء ومقدمي الرعاية

تمت المراجعة 28 يونيو 2022

Download

FACT SHEET FOR HEALTHCARE 
PROVIDERS

 

Revised 7/6/22

Download

HOJA INFORMATIVA PARA PROVEEDORES DE ATENCIÓN MÉDICA

Revisado 6 de julio de 2022

Download

FICHE D’INFORMATION DESTINÉE AUX
PROFESSIONNELS DE SANTÉ

Révision 6 juillet 2022

Download

FICHA INFORMATIVA PARA PRESTADORES DE CUIDADOS DE SAÚDE

Revisto 6 de julho de 2022

Download

صحيفة الحقائق لمقدمي الرعاية الصحية

 

تمت المراجعة 6 يوليو 2022

Download

STANDARD DOSING 
INFORMATION GUIDE​​

 

Revised 5/19/22

Download

DOSING INFORMATION GUIDE FOR PATIENTS WITH MODERATE
KIDNEY DISEASE

Revised 5/19/22

Download
Related Pages How to Take Possible Side Effects
How to verify your tablets are authentic

PAXLOVID must be prescribed by a licensed healthcare provider and supplied by a government approved pharmacy or medical facility.

Authentic PAXLOVID, from Pfizer Inc., will include the Pfizer name on the label and will be packaged in 5 aluminum push-through blister cards. Individual doses are not for sale. PAXLOVID will be packaged in a rectangular carton. The carton has a colorless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over, and these repeating features are seen in a contrasting matte finish.

PAXLOVID consists of tablets for a 5-day oral treatment regimen, with morning and evening doses.

NOTE: If you are a patient with moderate kidney disease, you may receive a carton with daily blister cards that have been altered to ensure you receive the correct dose.

To help determine whether the tablets are authentic, look for specific text on each side of the tablets

Tablet

Text

nirmatrelvir

Front: 3CL | Back: PFE

ritonavir, manufactured by AbbVie

Front:  iconNK | Back: No text

ritonavir, manufactured by Hetero

Front: H | Back: R9

Pfizer is committed to patient safety and ensuring that people have accurate information about the investigational drug PAXLOVID, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate PAXLOVID to protect patients from products that might be dangerous and lead to serious and life-threatening harm.

If you suspect the product you have received may be counterfeit, contact us at 1‑800‑438‑1985 or visit www.pfizersafetyreporting.com.

Not actual size
For more
information

Contact One of the Following Groups

For Medical Information visit www.pfizermedicalinformation.com or call 1‑800‑438‑1985

For General Product Inquiries call 1‑877‑C19PACK (1‑877‑219‑7225)

AUTHORIZED USE

​​​​​​The FDA has authorized the emergency use of PAXLOVID, an investigational medicine, for the treatment of mild-to-moderate COVID-19 in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]) with a positive test for the virus that causes COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, under an EUA.

PAXLOVID is investigational because it is still being studied. There is limited information about the safety and effectiveness of using PAXLOVID to treat people with mild-to-moderate COVID-19.

IMPORTANT SAFETY INFORMATION

Expand
​​​​​​Before taking PAXLOVID, tell your healthcare provider if you:
  • Have any allergies
  • Have liver or kidney disease 
  • Are pregnant or plan to become pregnant
  • Are breastfeeding a child
  • Have any serious illnesses

Some medicines may interact with PAXLOVID and may cause serious side effects.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
  • Your healthcare provider can tell you if it is safe to take PAXLOVID with other medicines.
  • You can ask your healthcare provider or pharmacist for a list of medicines that interact with PAXLOVID.
  • Do not start taking a new medicine without telling your healthcare provider.
     
Tell your healthcare provider if you are taking combined hormonal contraceptive. ​​​​​​PAXLOVID may affect how your birth control pills work. Females who are able to become pregnant should use another effective alternative form of contraception or an additional barrier method of contraception. Talk to your healthcare provider if you have any questions about contraceptive methods that might be right for you.
     
​​​​​​HOW TO TAKE PAXLOVID
  • PAXLOVID consists of 2 medicines: nirmatrelvir and ritonavir. The 2 medicines are taken together 2 times each day for 5 days.
    • Nirmatrelvir is an oval, pink tablet. 
    • Ritonavir is a white or off-white tablet.
  • PAXLOVID is available in 2 Dose Packs. Your healthcare provider will prescribe the PAXLOVID Dose Pack that is right for you.
  • If you have kidney disease, your healthcare provider may prescribe a lower dose. Talk to your healthcare provider to make sure you receive the correct Dose Pack.
  • Do not remove your PAXLOVID tablets from the blister card before you are ready to take your dose.
  • Take your first dose of PAXLOVID in the Morning or Evening, depending on when you pick up your prescription, or as recommended by your healthcare provider.
  • Swallow the tablets whole. Do not chew, break, or crush the tablets.
  • Take PAXLOVID with or without food.  
  • Do not stop taking PAXLOVID without talking to your healthcare provider, even if you feel better.
  • If you miss a dose of PAXLOVID within 8 hours of the time it is usually taken, take it as soon as you remember. If you miss the dose by more than 8 hours, skip the missed dose and take the next dose at your regular time. Do not take morning and evening doses of PAXLOVID at the same time. 
  • If you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away.​
  • If you are taking a ritonavir- or cobicistat-containing medicine to treat hepatitis C or Human Immunodeficiency Virus (HIV), you should continue to take your medicine as prescribed by your healthcare provider.

​​​​​​Talk to your healthcare provider if you do not feel better or if you feel worse after 5 days. 
​​​​
Do not take PAXLOVID if:
  • You are allergic to nirmatrelvir, ritonavir, or any of the ingredients in PAXLOVID.
  • You are taking any of the following medicines:
    • alfuzosin
    • amiodarone
    • apalutamide
    • carbamazepine
    • clozapine
    • colchicine
    • dihydroergotamine
    • dronedarone
    • eletriptan
    • eplerenone
    • ergotamine
    • finerenone
    • flecainide
    • flibanserin
    • ivabradine
    • lomitapide
    • lovastatin
    • lumacaftor/ivacaftor
    • lurasidone
    • methylergonovine
    • midazolam (oral)
    • naloxegol
    • pethidine
    • phenobarbital
    • phenytoin
    • pimozide
    • primidone
    • propafenone
    • quinidine
    • ranolazine
    • rifampin
    • St. John’s Wort (hypericum perforatum)
    • sildenafil (Revatio®) for pulmonary arterial hypertension
    • silodosin
    • simvastatin
    • tolvaptan
    • triazolam
    • ubrogepant
    • voclosporin

Taking PAXLOVID with these medicines may cause serious or life-threatening side effects or affect how PAXLOVID works.
These are not the only medicines that may cause serious side effects if taken with PAXLOVID. PAXLOVID may increase or decrease the levels of multiple other medicines. It is very important to tell your healthcare provider about all medicines you are taking because additional laboratory tests or changes in the dose of your other medicines may be necessary while you are taking PAXLOVID. Your healthcare provider may also tell you about specific symptoms to watch out for that may indicate that you need to stop or decrease the dose of some of your other medicines.
Possible side effects of PAXLOVID are:
  • Allergic Reactions. Allergic reactions can happen in people taking PAXLOVID, even after only 1 dose. Stop taking PAXLOVID and call your healthcare provider right away if you get any of the following symptoms of an allergic reaction:
    • hives
    • trouble swallowing or breathing
    • swelling of the mouth, lips, or face
    • throat tightness
    • hoarseness
    • skin rash
  • Liver Problems. Tell your healthcare provider right away if you have any of these signs and symptoms of liver problems: loss of appetite, yellowing of your skin and the whites of eyes (jaundice), dark-colored urine, pale-colored stools and itchy skin, or stomach area (abdominal) pain.
  • Resistance to HIV Medicines. If you have untreated HIV infection, PAXLOVID may lead to some HIV medicines not working as well in the future.
  • Other possible side effects include:
    • altered sense of taste
    • diarrhea
    • high blood pressure
    • muscle aches
    • abdominal pain
    • nausea
    • feeling generally unwell
These are not all the possible side effects of PAXLOVID. Not many people have taken PAXLOVID. Serious and unexpected side effects may happen. PAXLOVID is still being studied, so it is possible that all of the risks are not known at this time.There is no experience treating pregnant women or breastfeeding mothers with PAXLOVID. For a mother and unborn baby, the benefit of taking PAXLOVID may be greater than the risk from the treatment. It is recommended that you use effective barrier contraception or do not have sexual activity while taking PAXLOVID. If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.Contact your healthcare provider if you have any side effects that bother you or do not go away. Report side effects or problems with the appearance or packaging of PAXLOVID to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088, or you can report side effects to Pfizer Inc. at www.pfizersafetyreporting.com, by fax at 1-866-635-8337, or by calling 1-800-438-1985.Please see Fact Sheet for Healthcare Providers and Fact Sheet for Patients, Parents, and Caregivers.